GlassScriptPhysician profile
Christopher G Vendryes
NPI 1205986916
$5,803.61
in general payments reported to CMS, 2019-2025
28 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $1,054 · 2021: $2,125 · 2022: $1,045 · 2023: $28.37 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,401.61 | 2019-2022 | |
| Forte Bio-Pharma LLC | $682.06 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $452.50 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $444.61 | 2019-2021 | |
| Medtronic USA, INC. | $390.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.78 | 2019-2021 | |
| Boston Scientific Corporation | $140.45 | 2019-2025 | Spaceoar Vue System - 10ml |
| Pacira Pharmaceuticals Incorporated | $122.12 | 2020 | |
| Redhill Biopharma INC. | $105.79 | 2020-2022 | |
| Sentynl Therapeutics, INC. | $86.06 | 2019 | |
| Nevro Corp. | $83.49 | 2019-2021 | |
| Neotract INC. | $76.70 | 2020 | |
| Nalu Medical, INC. | $61.31 | 2021 | |
| Daiichi Sankyo INC. | $59.12 | 2019 | |
| Janssen Biotech, INC. | $57.37 | 2021-2025 | Erleada |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $45.43 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $38.73 | 2021 | |
| Biodelivery Sciences International, INC. | $29.49 | 2019 | |
| Sumitomo Pharma America, INC. | $28.37 | 2023 | Gemtesa |
| Protega Pharmaceutials INC | $20.97 | 2022 | |
| Vertos Medical, INC. | $20.38 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.88 | 2025 | Adstiladrin |
| Intercept Pharmaceuticals, INC. | $15.55 | 2021 | |
| West Therapeutics Development, LLC | $15.07 | 2020 | |
| Orexo US, INC. | $14.26 | 2020 | |
| Allergan, INC. | $13.24 | 2019 | |
| Horizon Therapeutics Plc | $12.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vendryes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.